Creative Biolabs Announces Updated CRO Services on Oncolytic Virus Engineering & Fc Characterization

The accredited scientist team at Creative Biolabs has announced some key service updates, mainly covering oncolytic virus engineering service and therapeutic antibody Fc characterization service.

New York City, New York Jan 2, 2023 (Issuewire.com) - Drawing upon the experience of serving the healthcare research community, Creative Biolabs has been committed to bringing together highly skilled experts with varied backgrounds. As a good start into the year 2023, some key service updates are announced to mainly cover oncolytic virus engineering service and therapeutic Fc characterization service.

- **Oncolytic Virus Engineering—One-Stop Viral Solution**

Powered by the OncoVirapy™ platform, reverse genetics technology, and bacterial artificial chromosome (BAC) technology, the scientist team at Creative Biolabs now offers oncolytic virus engineering services fulfilling the specific demands of research, preclinical study, and drug development. The team is experienced in manipulating oncolytic viruses to alter the capsid to reduce pathogenicity and immunogenicity, to secret antibodies to boost the anti-tumor immune response, to express cytokine/chemokine to attract immune cells migration to the tumor site, and even to be loaded with immune checkpoint inhibitors.

Featured services are as follows:

* Pathogenicity Manipulation: Adenoviruses with deletions in E1b gene, HSV-1 with deletions in the γ34.5 and α47 genes, etc.

* Immunogenicity Manipulation: Modification of the capsid, antibody secretion, etc.

* Antibody-expressing Oncolytic Virus: Tumor-targeting mAbs and immunomodulatory mAbs

* Cytokine/Chemokine-expressing Oncolytic Virus: CCL5 expressing oncolytic virus, interleukin 2 expressing oncolytic virus, etc.

* Immune Checkpoint Inhibitor-expressing Oncolytic Virus: CTLA-4 and PD-1 checkpoint molecules

- **Therapeutic AntibodyFc Characterization—Expedite Finding of New Biobetters & Biosimilars**

To support the development of biobetter or biosimilar therapies, Creative Biolabs provides a diversified portfolio of antibody Fc characterization services for antibody function regulation, covering the detection of opsonized particles, cell lysis, and leukocyte degranulation.

In particular, cell-based functional assays are available now for evaluating antibody effector functions. For the most common isotypes of therapeutic mAbs, Creative Biolabs provides pre-developed, pre-validated assays that can be implemented immediately for early testing, allowing faster and more economical characterization of the Fc region of the molecule. Assay services have been upgraded to cover C1q binding assays, Fc-gamma receptor binding assays, FcRn binding assays, and FcγRIIIA/

CD16a binding assays.

“We are a trusted partner to many top global pharmaceutical and biotech companies. And our relentless dedication to accuracy, timeliness, and regulatory rigor will enable your therapeutic innovations to reach patients faster,” introduced by a senior scientist at Creative Biolabs, “we are always open to talk about your experiment, your goals, and some of the challenges your team is facing, so please feel free to schedule a free consultation from our website at any time.”

About Creative Biolabs

With more than a decade of exploration and expansion, Creative Biolabs has gathered teams of experts with solid knowledge regarding antibody discovery, protein engineering, emerging immunotherapies, cell, and gene therapy, etc. The team focuses on the flexible customer-led project progression to adapt any service to clients’ specific projects. In addition to the dedicated services and products, clients are welcome to take a deep dive into topics of interest by browsing the collection of articles, blog posts, webinars, and more.

Media Contact

Creative Biolabs

marketing@creative-biolabs.com

Source : Creative Biolabs

See on IssueWire